IL4R and Alzheimer disease: The results of the present systematic review and meta-analysis are not intended to replace any approved treatment for AD, such as Dupilumab, an interleukin(IL)-4 receptor alpha (IL-4Rα) antagonist [101], which the FDA approved in March 2017 for patients aged 6 years and older with moderate-to-severe AD.